trial

Efficacy of Personalizing Cognitive Remediation for Schizophrenia by Targeting Impairments in Early Auditory Processing

NCTId NCT04554121
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 194 (actual)
Sponsored by Columbia University
Primary completion 2025-10-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
194 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2020-12-14
Primary completion
2025-10-24
Eligibility
ALL · 18 Years · 68 Years

Interventions & indications

Drugs
Brain BasicsBrain Training

Sponsors

Columbia UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Alice Medalia, Ph.D.Principal Investigator

Sites

9 total
Stamford, United StatesBrooklyn, United StatesBrooklyn, United StatesBrooklyn, United StatesBrooklyn, United StatesNew York, United StatesNew York, United StatesOrangeburg, United StatesThe Bronx, United States

Facts & assertions

4 sourced
Enrollment
194
Phase
NA
Primary Completion Date
2025-10-24
Status
COMPLETED
relationships
The graph out of here
drug
Brain Basics
drug
Brain Training
drug
lead_sponsor
Columbia University
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Alice Medalia, Ph.D.
person